What is REGN's five-year median P/E?

18.0x. Half of REGN's weekly readings over the last five years were higher and half were lower. This page has 758 weekly readings, from Apr 23, 2012 to Oct 26, 2026.

Does a low historical rank mean a stock is a buy?

No. The rank compares REGN only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Regeneron Pharmaceuticals (REGN) valuation

Health Care

$818.77

Latest weekly close · Market cap $86.8B

Within its usual range

Regeneron Pharmaceuticals' P/E of 20.2x is higher than 68% of its weekly readings over the last five years (as of Oct 30, 2026).

Forward P/E 12.8× (analyst estimates, not ranked).

Weekly P/E with its 5-year range

P/E each weekMiddle half of the last 5 years5-year median 18.0×

5-year median: 18.0×
10-year median: 19.7×
5-year low to high: 8.1× to 32.5×
Versus 5-year median: +12%

P/E

68thpercentile

of its weekly readings over the last five years

Growth, last 12 months vs the year before

Revenue: +9%accelerating
EPS: +2%

Price vs revenue and EPS, indexed to 100

Each line starts at 100 at its first positive reading over the last five years. Revenue and EPS change at fiscal quarter ends.

PriceRevenue, last 12 monthsEPS, last 12 months100 = first reading

P/E at each year-end

The last weekly reading of each year, and its percentile against the five years before it.

REGN P/E at each year-end
Year-end	P/E	5-year percentile	P/S	EV/Sales	EV/EBITDA
Dec 29, 2025	18.6×	62	5.8×	5.4×	18.2×
Dec 30, 2024	17.8×	41	6.0×	5.5×	17.0×
Dec 25, 2023	25.1×	90	7.6×	7.0×	19.8×
Dec 26, 2022	15.2×	34	5.9×	5.6×	11.7×
Dec 27, 2021	10.1×	2	5.3×	5.0×	8.8×
Dec 28, 2020	17.7×	12	6.7×	6.6×	16.3×
Dec 30, 2019	19.8×	16	5.5×	5.2×	16.0×
Dec 31, 2018	25.4×	6	7.2×	6.8×	17.5×
Dec 25, 2017	34.2×	9	8.0×	7.7×	21.0×
Dec 26, 2016	54.4×	25	9.0×	8.7×	31.5×

Health Care peers on P/E

Each percentile compares a stock with its own last five years.

Compare REGN with peers

Health Care peers of REGN on P/E
Stock	P/E	Versus its own history	5-year percentile
ABBVAbbVie	82.1×	Above its usual range	77
AMGNAmgen	28.6×	Above its usual range	80
ARWRArrowhead Pharmaceuticals Inc	n/m	Not ranked	n/m, not ranked
BIIBBiogen	107.6×	Historically high	100
BMRNBioMarin Pharmaceutical Inc	155.4×	Within its usual range	63

Appears in

Sector: Health Care
Screens: Nuclear Stocks: Valuation Screen
Semiconductor Equipment Stocks: Valuation Screen

Screen Health Care stocks the same way

Research on REGN

No articles about REGN yet. How valuation percentiles work

Loading peers and related research…

About this history

What is REGN's current P/E?: Regeneron Pharmaceuticals' P/E of 20.2x is higher than 68% of its weekly readings over the last five years (as of Oct 30, 2026).
What is REGN's five-year median P/E?: 18.0x. Half of REGN's weekly readings over the last five years were higher and half were lower. This page has 758 weekly readings, from Apr 23, 2012 to Oct 26, 2026.
Does a low historical rank mean a stock is a buy?: No. The rank compares REGN only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.